<DOC>
	<DOCNO>NCT01845675</DOCNO>
	<brief_summary>Temozolomide dacarbazine-based chemotherapy combine endostatin efficacy well-differentiated pancreatic neuroendocrine tumor</brief_summary>
	<brief_title>Temozolomide Dacarbazine-based Chemotherapy Plus Endostatin Advanced Pancreatic Neuroendocrine Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Endostatins</mesh_term>
	<criteria>1 . 18 year age old 2 . ECOG ≤2 3 . Pathologically confirm locally advanced metastatic welldifferentiated pancreatic neuroendocrine tumor . 4 . Prior treatment oneline chemotherapy allow , exception prior treatment temozolomide dacarbazine endostatin within past 6 month 5 . Disease progress last therapy 6 . Minimum 4 week since major surgery , completion radiation , completion prior systemic anticancer therapy 7 . Disease progress within past 12 months。 8 . Patients must least one measurable site disease accord RECIST1.1 criterion previously irradiate . 9 . Adequate bone marrow , liver renal function 10 . Life expectancy 3 month 11 . Patient inform consent。 1 . Concurrent use Octreotide drug may efficacy neuroendocrine tumor . 2 . 2 line prior chemotherapy。 3 . Patients severe and/or uncontrolled medical condition condition could affect participation study 4 . Uncontrolled infectious disease。 5 . Other malignancy within past 5 year except adequately treat carcinoma cervix basal squamous cell carcinoma skin 6 . Uncontrolled brain leptomeningeal metastases 7 . Patients know hypersensitivity temozolomide endostatin。 8 . Patient could take tablets。</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>temozolomide</keyword>
	<keyword>endostatin</keyword>
	<keyword>advanced</keyword>
	<keyword>well-differentiated</keyword>
	<keyword>pancreatic neuroendocrine tumor</keyword>
</DOC>